TY - JOUR
T1 - Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism
T2 - Evidence from marginal structural models used to adjust for time-dependent confounding
AU - Fukagawa, Masafumi
AU - Kido, Ryo
AU - Komaba, Hirotaka
AU - Onishi, Yoshihiro
AU - Yamaguchi, Takuhiro
AU - Hasegawa, Takeshi
AU - Kurita, Noriaki
AU - Fukuma, Shingo
AU - Akizawa, Tadao
AU - Fukuhara, Shunichi
N1 - Funding Information:
Support: The MBD-5D is supported by research grants from Kyowa Hakko Kirin , without restrictions on publications.
PY - 2014/6
Y1 - 2014/6
N2 - Background Hemodialysis patients with mineral and bone disorders (MBDs) have an abnormally high relative risk of death, but their absolute risk of death is unknown. Further, previous studies have not accounted for possible time-dependent confounding of the association between MBD markers and death due to the effect of markers of MBD on treatments, which subsequently may affect MBD markers. Study Design Multicenter, 3-year, prospective, case-cohort study. Setting & Participants 8,229 hemodialysis patients with secondary hyperparathyroidism (parathyroid hormone level ≥180 pg/mL and/or receiving vitamin D receptor activators) at 86 facilities in Japan. Predictors Serum phosphorus, calcium, and parathyroid hormone levels. Outcome All-cause mortality. Measurements Marginal structural models were used to compute absolute differences in all-cause mortality associated with different levels of predictors while accounting for time-dependent confounding. Results The association between phosphorus level and mortality appeared U-shaped, although only higher phosphorus level categories reached statistical significance: compared to those with phosphorus levels of 5.0-5.9 mg/dL (1.61-1.93 mmol/L), patients with the highest (≥9.0 mg/dL [≥2.90 mmol/L]) phosphorus levels had 9.4 excess deaths/100 person-years (rate ratio, 2.79 [95% CI, 1.26-6.15]), whereas no association was found for the lowest phosphorus category (<3.0 mg/dL [<0.97 mmol/L]; rate ratio, 1.54 [95% CI, 0.87-2.71]). Similarly, hypercalcemia (≥10.0 mg/dL [≥2.50 mmol/L]) was associated with excess deaths, and the highest level of hypercalcemia (≥11.0 mg/dL [≥2.75 mmol/L]) was associated with 5.8 excess deaths/100 person-years (rate ratio, 2.38 [95% CI, 1.77-3.21]) compared to those with levels of 9.0-9.4 mg/dL (2.25-2.37 mmol/L). Abnormally high parathyroid hormone levels were not associated with excess deaths. Limitations Possible residual confounding. Conclusions These results reinforce the idea that serum calcium (in addition to phosphorus) level is an important predictor of the absolute risk of death in hemodialysis patients with secondary hyperparathyroidism.
AB - Background Hemodialysis patients with mineral and bone disorders (MBDs) have an abnormally high relative risk of death, but their absolute risk of death is unknown. Further, previous studies have not accounted for possible time-dependent confounding of the association between MBD markers and death due to the effect of markers of MBD on treatments, which subsequently may affect MBD markers. Study Design Multicenter, 3-year, prospective, case-cohort study. Setting & Participants 8,229 hemodialysis patients with secondary hyperparathyroidism (parathyroid hormone level ≥180 pg/mL and/or receiving vitamin D receptor activators) at 86 facilities in Japan. Predictors Serum phosphorus, calcium, and parathyroid hormone levels. Outcome All-cause mortality. Measurements Marginal structural models were used to compute absolute differences in all-cause mortality associated with different levels of predictors while accounting for time-dependent confounding. Results The association between phosphorus level and mortality appeared U-shaped, although only higher phosphorus level categories reached statistical significance: compared to those with phosphorus levels of 5.0-5.9 mg/dL (1.61-1.93 mmol/L), patients with the highest (≥9.0 mg/dL [≥2.90 mmol/L]) phosphorus levels had 9.4 excess deaths/100 person-years (rate ratio, 2.79 [95% CI, 1.26-6.15]), whereas no association was found for the lowest phosphorus category (<3.0 mg/dL [<0.97 mmol/L]; rate ratio, 1.54 [95% CI, 0.87-2.71]). Similarly, hypercalcemia (≥10.0 mg/dL [≥2.50 mmol/L]) was associated with excess deaths, and the highest level of hypercalcemia (≥11.0 mg/dL [≥2.75 mmol/L]) was associated with 5.8 excess deaths/100 person-years (rate ratio, 2.38 [95% CI, 1.77-3.21]) compared to those with levels of 9.0-9.4 mg/dL (2.25-2.37 mmol/L). Abnormally high parathyroid hormone levels were not associated with excess deaths. Limitations Possible residual confounding. Conclusions These results reinforce the idea that serum calcium (in addition to phosphorus) level is an important predictor of the absolute risk of death in hemodialysis patients with secondary hyperparathyroidism.
KW - Calcium
KW - clinical epidemiology
KW - death
KW - end-stage renal disease
KW - hemodialysis
KW - hyperparathyroidism
KW - hyperphosphatemia
KW - mineral metabolism
KW - parathyroid hormone (PTH)
UR - http://www.scopus.com/inward/record.url?scp=84901505238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901505238&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2013.08.011
DO - 10.1053/j.ajkd.2013.08.011
M3 - Article
C2 - 24119541
AN - SCOPUS:84901505238
SN - 0272-6386
VL - 63
SP - 979
EP - 987
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 6
ER -